867 Stock Overview
An investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China.
Snowflake Score | |
---|---|
Valuation | 6/6 |
Future Growth | 2/6 |
Past Performance | 2/6 |
Financial Health | 6/6 |
Dividends | 4/6 |
Rewards
Risk Analysis
China Medical System Holdings Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$6.94 |
52 Week High | HK$15.86 |
52 Week Low | HK$6.51 |
Beta | 0.82 |
11 Month Change | 3.58% |
3 Month Change | -44.57% |
1 Year Change | -46.12% |
33 Year Change | -67.49% |
5 Year Change | -3.07% |
Change since IPO | -51.67% |
Recent News & Updates
Recent updates
Shareholder Returns
867 | HK Pharmaceuticals | HK Market | |
---|---|---|---|
7D | -1.8% | -4.1% | 0.6% |
1Y | -46.1% | -3.5% | 2.4% |
Return vs Industry: 867 underperformed the Hong Kong Pharmaceuticals industry which returned -3.5% over the past year.
Return vs Market: 867 underperformed the Hong Kong Market which returned 2.4% over the past year.
Price Volatility
867 volatility | |
---|---|
867 Average Weekly Movement | 11.3% |
Pharmaceuticals Industry Average Movement | 5.5% |
Market Average Movement | 7.2% |
10% most volatile stocks in HK Market | 15.1% |
10% least volatile stocks in HK Market | 3.7% |
Stable Share Price: 867's share price has been volatile over the past 3 months.
Volatility Over Time: 867's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1995 | 5,701 | Kong Lam | web.cms.net.cn/zh/home/ |
China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China. Its products include VALTOCO, a diazepam nasal spray to treat seizure clusters; Plendil for the treatment of hypertension and stable angina pectoris; XinHuoSu to treat acute heart failure; Deanxit for mild-to-moderate depression, anxiety, and psychosomatic affections; METOJECT, a methotrexate injection for recalcitrant disabling psoriasis; and Ursofalk for the treatment of cholesterol gallstones in the gallbladder, cholestatic liver disease, and biliary reflux gastritis. The company also offers Salofalk for treating Ulcerative Colitis and Crohn’s disease; Bioflor for the treatment of diarrhea; Combizym for dyspepsia; ILUMETRI, a tildrakizumab injection to treat moderate-tosevere plaque psoriasis; Augentropfen Stulln Mono eye drops to treat senile macula degeneration and asthenopia; and Hirudoid for blunt traumata with or without hematomas and superficial phlebitis insofar.
China Medical System Holdings Limited Fundamentals Summary
867 fundamental statistics | |
---|---|
Market cap | HK$16.93b |
Earnings (TTM) | HK$2.58b |
Revenue (TTM) | HK$8.61b |
6.4x
P/E Ratio1.9x
P/S RatioIs 867 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
867 income statement (TTM) | |
---|---|
Revenue | CN¥8.01b |
Cost of Revenue | CN¥1.94b |
Gross Profit | CN¥6.08b |
Other Expenses | CN¥3.68b |
Earnings | CN¥2.40b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 0.98 |
Gross Margin | 75.82% |
Net Profit Margin | 29.96% |
Debt/Equity Ratio | 8.3% |
How did 867 perform over the long term?
See historical performance and comparison